论文部分内容阅读
氟卡胺具有许多第一类抗心律失常药物的特性,初步临床试用显示具有显著或完全抑制室性心律失常的作用。动物实验显示,该药有负性心收缩力作用。本文观察其对严重心脏病,特别是对冠心病患者有否不利的负性心收缩力作用。方法:10例新近有过急性心肌梗塞的患者,先测定基础情况下血流动力学参数,然后作左心室和冠状动脉造影。在30分钟期间以恒速静脉注射氟卡胺2毫克/公斤,在氟卡胺注射完毕后15分钟,重复血流动力学测定并作第二次心室造影。最后6例在
Flecainide has many of the first class of anti-arrhythmic drug properties, the initial clinical trial showed significant or complete inhibition of ventricular arrhythmias role. Animal experiments show that the drug has negative cardiac contractility. This article observes its serious heart disease, especially for patients with coronary heart disease negative adverse cardiac contractility. Methods: Ten patients with recent acute myocardial infarction were enrolled in the study. Baseline hemodynamic parameters were measured before left ventricular and coronary angiography. Flecainide 2 mg / kg was intravenously administered at a constant rate over a 30-minute period and the hemodynamics were repeated 15 minutes after the completion of flecainide injection and a second ventricular angiography was performed. The last 6 cases are there